Saridegib | 1037210-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Saridegib
• 英文别名: N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S,Z)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7,8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulene]-3'-yl)methanesulfonamide；IPI-926；N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide
• CAS: 1037210-93-7
• 化学式: C₂₉H₄₈N₂O₃S
• 分子量: 504.778
• InChiKey: HZLFFNCLTRVYJG-WWGOJCOQSA-N

物化性质

• 沸点：
  617.7±65.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 储存条件：
  2-8℃

制备方法与用途

Saridegib是Smo的特异性有效抑制剂，它是 Hedgehog 信号通路中的一个关键跨膜信号蛋白。

反应信息

• 作为反应物：
  描述：

  Saridegib 在 盐酸 作用下， 以 异丙醇 为溶剂， 以11.5 kg的产率得到IPI-926盐酸盐
  参考文献：
  名称：

  A Design of Experiments Approach to a Robust Final Deprotection and Reactive Crystallization of IPI-926, A Novel Hedgehog Pathway Inhibitor

  摘要：

  A design of experiments (DoE) approach was taken to optimize purity and reaction yield of the final debenzylation and hydrochloride salt formation of IPI-926. The study involved a careful dissection of the different process steps to enable an independent investigation of these steps while ensuring that process streams were representative. The results enabled a streamlined process from the final chemical transformation to the salting and isolation and led to the elimination of variability in the process as well as a robust control of impurities. The optimized process was applied to production and demonstrated on the kilogram scale.

  DOI：

  10.1021/acs.oprd.5b00214
• 作为产物：
  描述：

  benzyl (3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3-azido-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-carboxylate 在 palladium 10% on activated carbon 氢气 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 4.5h， 生成 Saridegib
  参考文献：
  名称：

  [EN] ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
  [FR] TRANSAMINATION ENZYMATIQUE D'ANALOGUES DE CYCLOPAMINE

  摘要：

  提供从酮起始材料合成氨基类似物的过程。

  公开号：

  WO2011017551A1

文献信息

• [EN] HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF<br/>[FR] INHIBITEURS DE LA VOIE SIGNALISATION HEDGEHOG ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：ZHANG XIAOHU

  公开号：WO2014113191A1

  公开（公告）日：2014-07-24

  The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders).

  刺猬（Hh）信号通路是一条在胚胎发育过程中调节图案形成、生长和细胞迁移的通路，但在成年后仅限于组织维护和修复。抑制性通路组分的突变失活导致刺猬信号通路的成熟配体无关激活，导致基底细胞癌和髓母细胞瘤等癌症的发生。刺猬信号的配体依赖性激活参与前列腺癌、胰腺癌、乳腺癌和血液癌的发生。因此，抑制异常的刺猬信号代表了一种有前途的新型抗癌疗法。该发明提供了一种抑制刺猬通路信号的化合物I的新分子，并为治疗恶性肿瘤（基底细胞癌、髓母细胞瘤、胶质母细胞瘤、非小细胞肺癌、前列腺癌、胰腺癌、血液癌、间叶细胞癌等）、预防肿瘤再生长、增强放疗和化疗的敏感性以及其他疾病（炎症、纤维化和免疫紊乱）的治疗应用。
• Transfer Hydrogenation of Cyclopamine Analogs
  申请人：Genov Daniel G.

  公开号：US20120065399A1

  公开（公告）日：2012-03-15

  Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

  本文提供了一种用于将似jervine型Veratrum生物碱的酮类似物（如环毒素）进行转移氢化的方法。本文还提供了新型的钌转移氢化催化剂。
• [EN] TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS<br/>[FR] HYDROGÉNATION PAR TRANSFERT D'ANALOGUES DE CYCLOPAMINE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2012037217A1

  公开（公告）日：2012-03-22

  Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

  本文提供了一种用于转移氢化物的过程，适用于jervine型Veratrum生物碱的酮类似物，如环状毒草碱。本文还提供了新颖的铑转移氢化催化剂。
• TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20170029433A1

  公开（公告）日：2017-02-02

  Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

  本文提供了一种将拟麻酮类似物，如环状毒草碱转移氢化的方法，例如环状毒草碱。本文还提供了新型的钌催化剂用于转移氢化反应。
• [EN] METHODS FOR STEREOSELECTIVE REDUCTION<br/>[FR] PROCÉDÉS DE RÉDUCTION STÉRÉOSÉLECTIVE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2009086451A1

  公开（公告）日：2009-07-09

  The invention is directed to a method to reduce a C-C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.

  本发明涉及一种方法，用于还原类固醇化合物的烯酮的C-C双键，以产生β酮产物和α酮产物的混合物，包括在催化剂和取代吡啶的存在下，用氢气处理类固醇化合物在溶剂中的溶液或悬浮液。